Project Number 5R21AG047484-02 Agency/Funding Organization NIA Funding Year 2015 View Full Project Details for POLYTHERAPY FOR AD: COMBINING GAMMA-SECRETASE MODULATION AND CRFR1 ANTAGONISM Research Categorization Primary Disease / Condition Alzheimer's Disease CADRO Category C. Translational Research and Clinical Interventions 4. Non-clinical Drug Development (small molecules and biologics) r. Multi-target Researcher and Organization Principal Investigator WAGNER, STEVEN LEE Principal Investigator First Name WAGNER Principal Investigator Last Name STEVEN LEE Awardee Organization UNIVERSITY OF CALIFORNIA SAN DIEGO Awardee State California Contact PI Country United States Project Detail Funding Opportunity Announcement PA-13-303: NIH Exploratory/Developmental Research Grant Program (Parent R21) FY Overall Cost $225,525 Funding Organization Agency/Funding Organization NIA Funding Organization Country United States Program Official REFOLO, LORENZO Related Resources Repository [AlzPED] CRF receptor-1 antagonism mitigates Aβ pathology and cognitive and synaptic deficits in a mouse model of Alzheimer's disease [AlzPED] Corticotropin-Releasing Factor Receptor-1 Antagonism Reduces Oxidative Damage in an Alzheimer’s Disease Transgenic Mouse Model.
